MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Gene Therapy

Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing

PloS one 2018 January [Link] Patch AM et. al. Abstract Technological innovation and increased affordability have contributed to the widespread adoption of genome sequencing technologies in biomedical research. In particular large cancer research consortia have embraced next generation sequencing, and have used the technology to define the somatic mutation landscape of multiple cancer types. These […]

Comments Off on Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing

A genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma

Journal of Toxicology 2017 December [Epub ahead of print] [Link] Crovella S. et.al. Abstract The presence of asbestos bodies (ABs) in lung parenchyma is considered a histopathologic hallmark of past exposure to asbestos fibers, of which there was a population of longer fibers. The mechanisms underlying AB formation are complex, involving inflammatory responses and iron […]

Comments Off on A genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Journal of Thoracic Oncology 2017 October [Epub ahead of print] [Link] Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, relatively chemo- and […]

Comments Off on Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Weight of evidence analysis for assessing the genotoxic potential of carbon nanotubes

Critical Reviews in Toxicology 2017 September [Epub ahead of print] [Link] Møller P, Jacobsen NR Abstract Carbon nanotube (CNT) is a nanomaterial that has received interest because of its high-tensile strength and low weight. Although CNTs differ substantially in physico-chemical properties, they share high aspect ratio which resembles that of asbestos and other fibers causing […]

Comments Off on Weight of evidence analysis for assessing the genotoxic potential of carbon nanotubes

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

JAMA Oncology 2017 September [Epub ahead of print] [Link] Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, Godleski JJ, Crum CP, Chirieac LR Abstract IMPORTANCE: Malignant peritoneal mesothelioma is a rare, aggressive tumor arising from the peritoneal lining, induced by asbestos, therapeutic radiation, or germline mutations. Nevertheless, the molecular features […]

Comments Off on Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

Magnetic nanoparticles-based therapy for malignant mesothelioma

Romanian Journal of Morphology and Embryology [2017] [Link] Mîndrilă I, Buteică SA, Mihaiescu DE, Burada F, Mîndrilă B, Predoi MC, Pirici I, Fudulu A, Croitoru O Abstract This work was aimed to analyze the versatility of the chick embryo chorioallantoic membrane (CAM) as in vivo model for the study of the malignant pleural mesothelioma (MPM) […]

Comments Off on Magnetic nanoparticles-based therapy for malignant mesothelioma

Targeting the epigenome in malignant pleural mesothelioma

Translational Lung Cancer Research 2017 June [Link] McLoughlin KC, Kaufman AS, Schrump DS Abstract Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities. Recent insights regarding epigenetic alterations in MPM provide the preclinical rationale for the evaluation of novel combinatorial regimens targeting the epigenome in these neoplasms.

Comments Off on Targeting the epigenome in malignant pleural mesothelioma

Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers

Discovery Medicine 2017 May [Link Rimkus T, Sirkisoon S, Harrison A, Lo HW Abstract Tumor suppressor candidate 2 (TUSC2, also known as FUS1) was identified in 2000 as a candidate tumor suppressor gene located in a region on chromosome 3p21.3 that is homozygously deleted in some lung and breast cancers. The deletion is rare in […]

Comments Off on Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Expert Opinion of Investigational Drugs 2017 July 6 [Epub ahead of print] [Link] Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L Abstract INTRODUCTION: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to […]

Comments Off on Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma

BMC Cancer 2017 June 2 [Link] Sneddon S, Patch AM, Dick IM, Kazakoff S, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J Abstract BACKGROUND: Malignant mesothelioma (MM) is an aggressive cancer of the pleural and peritoneal cavities caused by exposure to asbestos. Asbestos-induced mesotheliomas in wild-type mice have been used extensively […]

Comments Off on Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma